Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR882 in Participants With Gout
NCT06439602Phase 3Completed
- Sponsor
- Arthrosi Therapeutics
- Start
- Jun 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of pozdeutinurad in gout, sponsored by Arthrosi Therapeutics. Started Jun 2024; status: completed.
02
Drugs
pozdeutinurad
03
Conditions
gout
Beyond the preview
Go deeper on NCT06439602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06439602.